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A lthough much psychiatric research is based on randomized controlled trials (RCTs), where patients are randomly assigned to treatments, sometimes RCTs are not ethical nor feasible. Ethical concerns might preclude randomization, such as when evaluating whether "light cigarettes" produce less health risk by potentially randomizing subjects to smoke different brands, or it may be impractical, such as when the treatment of interest is widely available and commonly used. When RCTs are unethical or infeasible, a carefully constructed nonexperimental study can often be used to estimate treatment effects. Although nonexperimental studies are disadvantaged by lack of randomization, the study costs may be lower, the study sample may be broader, and follow-up may be longer, as compared to an RCT. [1] [2] [3] The causal effect of a treatment can be unambiguously identifi ed in studies where we are confi dent that the only difference between those subjects who take one treatment versus another is exposure to the intended treatments. By virtue of randomization, RCTs ensure, on average, the treatment and comparison groups are similar on baseline characteristics, both those that are measured as well as unmeasured ones. In nonexperimental studies, there is no such guarantee, but as we will see, there are some analytic approaches that can reduce differences. If treatment and comparison groups systematically differ on baseline factors that are correlated with the outcome, we say there is "selection bias." Selection bias leads to confounding, "a situation in which the estimated intervention effect is biased because of some difference between the comparison groups (apart from the intended interventions), such as baseline characteristics or prognostic factors. For a factor to be a confounder, it must differ between the comparison groups and predict the outcome of interest." 4 Numerous design and analytic strategies are available to account for measured confounders. Well-designed nonexperimental studies make good use of measured confounders by creating treatment groups that look as similar as possible on the measured characteristics. Researchers then generally need to assume that, given comparability (or balance) between the groups on measured confounders, there are no measured or unmeasured differences, other than treatment received. This assumption has many names: "unconfounded treatment assignment," "no hidden bias," "ignorable treatment assignment," or "selection on observables." [5] [6] [7] In this article, we describe nonexperimental approaches that create balance between treatment groups. The key idea is to use relatively recently developed techniques, known as propensity score methods, to ensure that the treatment and comparison subjects are as similar as possible. The goal is to replicate a randomized experiment, at least with respect to the measured confounders, by making the treatment and comparison groups look as if they could have been randomly assigned to the groups, in the sense of having similar distributions of the confounders. The sections of this article describe the fi ve key stages to this process (see Table 1 , page 721). The fi rst section (Step 1) discusses defi ning and identifying the groups, then (Step 2) we outline the methods available for adjusting for covariate differences. We will also provide ways of assessing those differences (Step 3). We will also show how to estimate the treatment effects (Step 4), and then we discuss potential unobserved confounding (Step 5). We end with future considerations and conclusions.
We illustrate these propensity score methods using a study that compares atypical and conventional antipsychotic medications with regard to their effect on adverse metabolic outcomes (dyslipidemia, type II diabetes, and obesity). 17 The study uses data from Florida Medicaid benefi ciaries (18 to 64 years), who were diagnosed with schizophrenia and continuously enrolled from 1997 to 2001 . There have been a few RCTs that have been used to assess the metabolic effects of antipsychotic drugs. 18, 19 Findings of these RCTs, which exclude a large portion of schizophrenic patients and test single drugs, are generally regarded as unrepresentative of the adverse events of these drugs as used in routine practice. A notable exception is Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE), 20 a randomized effectiveness trial that enrolled a much broader group of patients. However, by far the bulk of the evidence on the causal associations of antipsychotics comes from studies using U.S. and U.K. administrative and medical databases.
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STEP 1: DEFINING THE TREATMENT AND COMPARISON GROUPS
The fi rst step involves clearly specifying the treatment of interest and identifying individuals who experienced that treatment. One way to address this is to In particular, we compare atypical antipsychotics (specifi cally, clozapine, olanzapine, quetiapine, and risperidone) to conventional antipsychotics (specifically, chlorpromazine, trifl uoperazine, fl uphenazine, perphenazine, thioridazine, haloperidol, and thiothixene). In this observational study, we use Medicaid claims data to examine outcomes for patients with fi lled prescriptions of these antipsychotic medications. We classify atypical (conventional) antipsychotic medication users as those subjects who fi lled at least one prescription for an atypical (conventional) antipsychotic during the time period examined. Prescribing information is unavailable and so only subjects who were written an antipsychotic prescription and fi lled it are included. Like an intent-to-treat analysis, we only know that the prescription was fi lled and not whether the medication was actually taken. See Tchernis et al 17 for more details on the sample and measures.
The next consideration is identifi cation of confounders: factors that have previously been found to be associated with receipt of atypical versus typical antipsychotics and with metabolic outcomes. In addition, confounders should be measured before treatment assignment to ensure that they are not affected by the treatment. 22, 23 Key confounders in the Medicaid study include demographic and clinical variables, listed in Table 2 (see page 722), such as sex, age, race, and medical comorbidities. A good study will use a dataset that has a large set of measured confounders so that the assumption of no hidden bias is more likely to be satisfi ed.
Once the treatment group, comparison group, and potential confounders are identifi ed, researchers need to identify data on those groups and the confounders. The particular data elements necessary are: subjects, some of whom received the treatment (atypical antipsychotics) and others the comparison condition (conventional antipsychotics), an indicator for which subject is in which group, potential confounders, and outcomes. Ideally, the confounders are measured before the treatment and the outcomes after the treatment, to ensure temporal ordering. Unfortunately, often it is not possible to have truly longitudinal data, and researchers instead use cross-sectional data and make assumptions regarding the time ordering of the variables being measured. In the Medicaid study, we determined periods during which an individual had some minimal exposure to an antipsychotic drug, at least 6 months of Medicaid enrollment preceding treatment initiation (from which we obtained the covariate information), and a 12-month follow-up period to examine incidence of metabolic outcomes. We analyze one measurement occasion for each subject, measured 12 months following antipsychotic initiation. (See Marcus et al for methods for estimating causal effects with multiple outcome occasions.) 24 Table 2 (Columns 1-3; see page 722) compares the means of the potential confounders between atypical and conventional antipsychotic users. The differences in percentages (for binary variables) or standardized differences (for continuous variables) are also reported. The standardized difference is the difference in means divided by the standard deviation of the confounder among the full set of conventional users. 1, 12, 25 We then multiply by 100 to express the difference as a percentage. The conventional users are older on average (by 26% of a standard deviation) and more likely to be black (34% vs. 24%), as compared with the atypical users. Because of these differences between the groups, comparing the raw outcomes between the two treatment groups would likely result in bias. 26 Statistical adjustments are required to deal with the differences in the observed confounders. 
STEP 2: METHODS FOR ADJUSTING FOR COVARIATE DIFFERENCES
Recommended Steps in Analyzing Nonexperimental Studies
Step Rationale Ideally, we want to compare atypical and conventional users who have "exactly" the same values for all the confounders. Assuming no unmeasured confounders, any difference in the outcomes could then be attributed to the treatment. However, exact matching on all of the covariates is often infeasible given the large number of covariates and relatively small number of subjects available. In the Medicaid study, if we were to make each of our 11 confounders binary, we would have 2048 (= 2 11 ) distinct strata and need to have both atypical and conventional antipsychotic users in each. Because this is not feasible, a reasonable strategy is to make the "distributions" of the confounders similar between the atypical and conventional antipsychotic users (eg, similar age, similar race, similar chronic medical comorbidity status). There are several general strategies to create comparable groups.
Regression Adjustment
A common approach to adjusting for confounders is regression adjustment, whereby the treatment effect is estimated by regressing the outcome of interest on an indicator for the treatment received and the set of confounders. The coeffi cient on the treatment indicator provides an estimate of the treatment effect (see Table 3 , Column 1, page 723). A drawback to this approach is that if the atypical and conventional groups are very different on the observed covariates (eg, with more than a 25% standard deviation difference on average age, as seen in Table 2 ), the regression adjustment relies heavily on the particular model form and extrapolates between the two groups. 26, 27 Why does this pose a problem? First, the regression approach will provide a prediction of what would have happened to atypical users had they instead used conventional antipsychotics using information from a set of conventional users who are very different from (eg, older than) those atypical users. Second, in most cases, the regression approach assumes a linear relationship between the measured covariates and the outcome of interest -an assumption that may not be true and is often diffi cult to test. Third, the output of standard regression analysis provides no information regarding covariate bal- ance between the two treatment groups.
Other approaches, which we now turn to, avoid these problems by ensuring that the comparisons are made between groups that are similar.
Propensity Score Methods
A useful tool to achieve comparable confounder distributions is the "propensity score," defi ned as the probability of receiving the treatment given the measured covariates. 7 A property of the propensity score makes it possible to select subjects based on their similarity with respect to the propensity score (a single number summary of the covariates, similar to a comorbidity score) in order to achieve comparability on all of the measured confounders, rather than having to consider each confounder separately. If a group of subjects have similar propensity scores, then they have similar probabilities of receiving the treatment, given the measured confounders. Within a small range of propensity score values, the atypical and conventional users should only differ randomly on the measured confounders, in essence replicating a randomized experiment.
Because the true propensity score for each subject is unknown, it is estimated with a model, such as a logistic regression, predicting treatment received given the measured confounders. Each subject's propensity score is their predicted probability of receiving the treatment, generated from the model. The diagnostics for propensity score estimation are not the standard logistic regression diagnostics, as concern is not with the parameter estimates or predictive ability of the model. Rather, the success of a propensity score model (and subsequent matching or stratifi cation procedure) is determined by the covariate balance achieved. Below we describe several ways that propensity scores can be used.
Nearest Neighbor Matching
One of the simplest ways of ensuring the comparability of groups is to select for each treated individual the comparison individual with the closest propensity score. 28 (Often the matches are based on the logits, the log-odds of the predicted probabilities, because the logits have better statistical properties.) We illustrate a 1:1 matching algorithm where one conventional antipsychotic user is selected for each atypical antipsychotic user. Variations on this algorithm include selecting multiple matches for each atypical user, matching atypical users to a variable number of conventional users, 29 and prioritizing certain variables. 13 For example, if there are a large number of potential control subjects relative to the number of treated, it may be possible to get two or three good matches for each treated individual, which will increase the precision of estimates without sacrifi cing much balance. 29, 30 In our study, because the numbers of conventional and atypical users are nearly equal, we used matching with replacement, meaning that each conventional user could be used as a match multiple times. 31 The Figure, Panel A (see page 724), illustrates the resulting matches in the Medicaid study, with 1,809 conventional users matched to the 3,384 atypical users. The x-axis refl ects the propensity scores; the y-axis is used to group the subjects into atypical (treated) vs. conventional (control), and matched vs. unmatched; the vertical spread of the symbols within each grouping is done to show the symbols more clearly. The fi gure shows the relative weight different subjects receive in the analyses of the outcomes, with the relative size of the symbols refl ecting the number of times a subject was matched. Thus, conventional users selected as a match multiple times have larger symbols. The goal is to see good "overlap" between the propensity scores of the atypical and conventional users, which we have. Table 4 (see page 725).
*Although our outcomes are binary, we present results from a linear regression model. This was for comparability with the analyses described for the propensity score approaches with weights. If a logistic regression model is used, the difference in absolute risk can be obtained by comparing predictions of the outcomes for the full sample under each of the treatment conditions. In this study, the results are virtually identical. Step 4 (see page XXX) provides more detail.
However, there are quite a few conventional users with low propensity scores who are left unmatched. This illustrates a common drawback of nearest neighbor matching, in that sometimes subjects are unmatched, including some with propensity scores similar to those in the other group.
Weighting
A second approach, inverse probability of treatment weighting (IPTW), avoids this problem by using data from all subjects. 10, 14, 32 The idea of IPTW is similar to that of survey sampling weights, where individuals in a survey sample are weighted by their inverse probabilities of selection so that they then represent the full population from which the sample was selected. In our setting, we treat each of the treatment groups (the atypical users and the conventional users) as a separate sample and weight each up to the "population," which in this case is all study subjects. Each subject receives a weight that is the inverse probability of being in the group that they are in. However, instead of having known survey sampling probabilities, we use the estimated propensity scores. In particular, atypical users are weighted by one over their probability of receiving an atypical antipsychotic (the propensity score) (ie, the weight for a user of atypical antipsychotics with a propensity score of 0.1 would be 10). Conventional users are weighted by one over their probability of receiving a conventional antipsychotic (one minus the propensity score). In the Medicaid study, the conventional users with low probabilities of receiving a conventional antipsychotic will receive relatively large weights, because they actually look more similar to the atypical users, thus providing good information about what would happen to the atypical users if they had instead taken conventional antipsychotics.
Subclassifi cation
Subclassifi cation, also called stratifi cation, is a method that also uses all subjects, by forming groups (subclasses) of individuals with similar propensity scores. 33 This is done by sorting the propensity scores and forming some number of subclasses (eg, 10), based on the percentiles (eg, deciles) in which each individual's propensity score falls. In the Medicaid study, the subclasses were created to have approximately the same number of subjects taking atypical antipsychotics (about 565); the number of conventional users in each subclass ranges from 287 to 933 (Figure, Panel B ; also see Table 4 , page 725). Because of the properties of propensity scores described above, within each subclass, the subjects look similar on the measured confounders. When a relatively small number of subclasses are formed, there are sometimes still differences within subclasses; 14 in those cases it may make sense to create more subclasses or use more sophisticated methods such as full matching, which forms many subclasses in a way that minimizes the differences in the propensity scores. 
Remarks
Is it better to match or to stratify/ weight? The answer depends on whether the investigator is more concerned about bias or about having enough power to detect an effect. Matching approaches are often used when it is important to reduce as much as possible differences between treatment groups and consequently, not all subjects are used, reducing the total sample size available to fi nd differences. Although subclassifi cation and weighting retain all subjects (generally yielding some effi ciency gain), there is a risk of making comparisons between individuals who are not as alike as desired.
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STEP 3: ASSESSING MEASURED CONFOUNDING
How do we know if the atypical and conventional groups are "similar," at least on the measured covariates? After using one of the approaches described above, the crucial next step is to check the resulting "balance": the similarity of the confounders between the treatment and comparison groups. Common (and sometimes misguided) measures used for balance checks are standard hypothesis tests, such as ttests. The danger in using test statistics is that they confl ate changes in balance with changes in the sample size; comparing P values before and after matching can be misleading, implying that balance has improved, when in fact it has not. 1, 12 A good balance measure, and the one we suggest, is the standardized difference in means. This is most appropriate for continuous variables. A general rule of thumb is that an acceptable standardized difference is less than 10%. 12 Differences larger than 10% roughly imply that 8% or more of the area covered by atypical and conventional users combined is not overlapping. For binary variables the absolute value of the difference in proportions is examined. These measures are generally calculated both in the full dataset (see Table 2 , Column 3, page 723,), as well as in the dataset after applying one of the propensity score methods described above (see Table 2 , Column 4, page 722); if the propensity score method was successful the standardized differences and differences in proportions should be smaller than they were in the original data set. After 1:1 matching (see Table 2 , Column 4) the largest standardized difference is 3%, which is a good situation. Similar balance was achieved with weighting and subclassifi cation. In contrast, the largest standardized difference prior to matching was 26%, which is clearly an unacceptable situation. In some cases adequate balance may not be achieved with the available data. This is an indication that estimating the treatment effect with that data may be unreliable. It may be necessary to add interactions of the measured covariates in the propensity score model, seek additional data sources, or reconsider the question of interest.
STEP 4: ESTIMATING THE AVERAGE TREATMENT EFFECT
Once adequate balance is achieved, the next step is to estimate the treatment effect. Note that this is the fi rst time that the outcome is used; the propensity score method itself is not selected or implemented using the metabolic outcome measures, beyond the idea of selecting confounders that may be correlated with the outcome(s).
Regression Adjustment
One method of estimating the treatment effect is to regress the outcomes for subjects in the original (unmatched) dataset on the measured confounders. In the antipsychotic study, we estimated a linear regression, where the coeffi cient of the atypical antipsychotic variable represents the increase (or decrease) in risk for atypical users. The results of this approach are shown in Table 3 , Column 1 (see page 723), where atypical antipsychotic use increases the risk of dyslipidemia and of obesity. This regression is easy to conduct, but has the drawbacks discussed above, particularly when the treatment groups are far apart on the covariates. However, despite these limitations of regression adjustment in general, in fact, combining it with the propensity score methods described above has been found to be a very effective approach, 11, [34] [35] [36] and we use that approach for the remaining methods. .61 on 1 degree of freedom P = 0.0001): 5% of the 3,384 pairs had discordant outcomes and in 65% of the discordant pairs, the atypical subject had obesity.
Alternatively, any analysis that would have been conducted on the full dataset can instead be conducted on the matched dataset. 11 We estimated a regression model with each metabolic outcome predicted by whether someone took an atypical antipsychotic and the measured confounders, using the matched sample. Because the matching was done with replacement, the regression analysis was run using weights to account for that design. 13 We fi nd that atypical antipsychotics increased the risk of obesity, but not dyslipidemia or type 2 diabetes (see Table 3 , Column 2, page 723), consistent with the results found using McNemar's test.
Weighting
After constructing IPTW weights, the effect estimate is obtained by estimating a weighted regression model using the IPTW weights.
14 The results are consistent with those of the standard regression adjustment, indicating increased risk of dyslipidemia and obesity for those taking atypical antipsychotics (see Table 3 , Column 3, page 723).
Subclassifi cation
With subclassifi cation, treatment effects are fi rst estimated separately within each subclass. Because of the potential for residual bias when the subclasses are relatively large, it is particularly important to estimate these effects using regression adjustment within each subclass, controlling for the confounders.
14 If the treatment effects are similar across subclasses, it may make sense to combine the subclass-specifi c estimates to obtain an overall estimate. The results for the antipsychotic study do not indicate substantial treatment differences across subclasses (see Table 4 , page 725). After combining the subclass results by taking a precision-weighted average of the effects within each subclass, we fi nd that the overall effects are similar to those from the simple regression adjustment and from weighting (see Table 3 , Column 4, page 723). An advantage of the subclassifi cation approach is that it permits a non-linear pattern in the effects across the subclasses.
Remarks
Selection of matching versus subclassifi cation or weighting involves a bias/ variance trade-off. One-to-one matching generally yields more closely matched samples and thus lower bias, but higher variance because of the smaller sample size used. The better balance generally obtained by matching also sometimes yields smaller point estimates of effects. In our example, the lack of a statistically signifi cant fi nding on dyslipidemia when using 1:1 matching but a signifi cant fi nding when using other approaches appears to be a result of a combination of these factors. In comparison with the effect on obesity, the effect of dyslipidemia is much weaker: for dyslipidemia, 53% of the discordant pairs had an atypical user with dyslipidemia (chi 2 = 2.613 on 1 degree of freedom; P = 0.11), for obesity, 65% of the discrepant pairs had an atypical user with obesity. The discrepancy in results also indicates the value in assessing sensitivity by trying a few different approaches; those that yield the best covariate balance should be used.
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STEP 5: ASSESSING UNMEASURED CONFOUNDING
The fi nal question in any nonexperimental study is how sensitive are the results to a potential unmeasured confounder. We illustrate an approach that determines how strongly related to the decision to fi ll an atypical antipsychotic medication an unmeasured confounder would have to be to make the observed effect go away (ie, lose statistical signifi cance). 37 We illustrate the approach using the matched pairs from 1:1 matching using the obesity outcome. Table 5 indicates that for two subjects who appear similar on the measured covariates, if their odds of fi lling an atypical antipsychotic medication differ by a factor of 1.5 or larger, then the treatment effect becomes statistically insignifi cant. The size of these odds needs to be interpreted in the context of the particular problem. In our analyses, the largest observed odds ratio was 1.75 (95% CI: 1.55, 1.98) refl ecting an increased odds of receiving an atypical antipsychotic for white subjects relative to black subjects. Given this sized odds ratio observed, the small number of confounders available in the data, and knowing that the results are sensitive at an odds of 1.5, makes us cautious in concluding that atypical antipsychotic use increases the risk of obesity compared to conventional antipsychotic use. These results need to be replicated in other studies.
FUTURE CONSIDERATIONS AND CONCLUSIONS
This article has provided an overview of the approaches for estimating treatment effects with nonexperimental data, with a focus on propensity score methods that ensure comparison of similar individuals. Although in this study the propensity score approaches gave results similar to those of traditional regression adjustment, we can have more confidence because of the balance obtained by the matching, weighting, and subclassification methods. The methods generally imply increased risk of dyslipidemia and obesity for individuals on atypical antipsychotics and no increased risk of Type II diabetes. However, we should interpret these results with caution, as the effect on dyslipidemia was sensitive to the particular method used and even the (stronger) effect on obesity is potentially sensitive to an unmeasured confounder.
There are a number of complications that researchers may encounter when designing an observational study. The fi rst is missing data: rarely do researchers measure all of the variables of interest for all study subjects. If there are not many patterns of missing data, a fi rst solution is to estimate separate propensity scores for each missing data pattern. 7 A second approach is to include missing data indicators in the propensity score model; this will essentially match individuals on both the observed values (when possible) and the patterns of missingness. 38, 39 A third approach is to use multiple imputation and undertake the propensity score matching and outcome analysis separately within each multiply imputed dataset. 40 A second complication involves questions where the treatment of interest is not a simple binary comparison. Interest might be in the effect of different types or dosages of antipsychotic medications. Two solutions exist in this type of setting. First, if scientifi cally interesting, focus can be shifted to a binary comparison, for example comparing low compared with high doses. Second, a new area of methodological research has developed generalized propensity scores for use with non-binary treatments. 5, 16, 41 Another concern in observational studies is that an outcome of interest, such as obesity, may be subject to ascertainment bias: a differential probability of ascertaining a condition based solely on the medication that is used. Ascertainment bias can also potentially occur in randomized trials when there is increased physician contact because of elevated side effects on active medication versus placebo. 42 When ascertainment bias occurs, propensity score methods are not suffi cient to provide appropriate adjustments.
A fi nal concern with any nonexperimental study is that of unmeasured confounding: there may be some unmeasured variable related to both which treatment an individual receives and their outcome. Using propensity score approaches to deal with measured confounders is an important step, but there is always concern about potential unmeasured confounders. One approach to assess whether this could be a problem is to examine an outcome that should not be affected by the treatment of interest; if an effect is actually found, that may indicate the presence of unmeasured confounding. We have also illustrated here a statistical sensitivity analysis, which can be used to assess how important such an unmeasured confounder may be with respect to the study conclusions. Instrumental variables methods, also known as "natural experiments," are another type of nonexperimental study that can be used when unmeasured confounding is of particular concern. Instrumental variables analyses do not rely on the assumption of no unmeasured confounding and instead rely on fi nding some "instrument" that affects the receipt of the treatment of interest but does not directly affect the outcomes. 43 What are the primary lessons? When reading a study that uses nonexperimental data, readers should:
• Consider whether the results are plausible, 44 • Examine whether the groups being compared are similar on the relevant variables, and • Consider whether there are potentially important confounders that were not measured.
When estimating treatment effects using nonexperimental methods, researchers should:
• Be clear about the treatment and comparison conditions,
• Identify data that has a large set of potential confounders measured, and • Ensure comparisons are made using similar individuals by using one of the propensity score methods described above.
In conclusion, propensity score approaches such as matching, weighting, and subclassifi cation are an important step forward in the estimation of treatment effects using observational data. Whenever treatment effects are estimated using nonexperimental studies, particular care should be taken to ensure that the comparison is being done using treated and comparison subjects who are as similar as possible; propensity scores are one way of doing so. Propensity score methods can thus help researchers, as well as users of that research, to have more confi dence in the resulting study fi ndings.
